Monday 16 December 2019 ,
Monday 16 December 2019 ,
Latest News
  • President, PM pay homage to Liberation War martyrs
  • 49th Victory Day today
  • Govt publishes list of 10,789 Razakars
  • Bangladesh boasts one of the most successful stories
  • Now Gazipur factory fire kills 10
  • Want to develop well-trained armed force: PM
  • 5 more die from Keraniganj fire: Death toll now 19
  • PM vows to make armed forces well trained
  • Six killed as protests flare
18 November, 2019 00:00 00 AM

FDA approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of H. pylori infection in adults

drugs.com
FDA approves Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of H. pylori infection in adults

RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases, recently announced that the U.S. Food and Drug Administration (FDA) has approved Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults. RedHill expects to launch Talicia1 in the U.S. in the first quarter of 2020 with its dedicated sales force.

Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies. It is estimated that H. pylori resistance to clarithromycin more than doubled between 2009-2013.

Professor David Y. Graham, MD, MACG, Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the Talicia Phase 3 studies, said: “Talicia offers patients a much-needed new treatment option for H. pylori with an excellent safety and efficacy profile that is not compromised by clarithromycin or metronidazole resistance. The clinical studies for Talicia demonstrated high efficacy in eradication of H. pylori. Studies with Talicia found zero resistance to rifabutin and showed 17% resistance to clarithromycin, a current standard-of-care macrolide antibiotic, consistent with current data showing that clarithromycin-containing therapies fail in approximately 25-40% of cases.”

Colin W. Howden, MD, AGAF, FACG, Hyman Professor of Medicine & Chief of the Division of Gastroenterology, University of Tennessee Health Science Center, added: “H. pylori is a major cause of peptic ulcer and gastritis. It is also carcinogenic and is the leading cause of gastric cancer.

Treatment of H. pylori infection has become increasingly difficult due to growing bacterial resistance and the lack of advances in treatment options over the past decade. Talicia offers a new effective treatment option to overcome bacterial resistance and provide optimal efficacy and I believe it could become a recommended first-line standard-of-care treatment for H. pylori infection.”

“The FDA’s approval of Talicia demonstrates our unwavering dedication to patients suffering from gastrointestinal diseases. We thank the patients, researchers and clinical staff who participated in the studies of Talicia and the RedHill team and vendors for this important milestone achieved by their commitment and hard work,” said Dror Ben-Asher, Chief Executive Officer of RedHill Biopharma. “We are working to expand our sales force to approximately 140 representatives who will promote Talicia, Aemcolo and other gastrointestinal-focused products in our basket.”

About Talicia

Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.

 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Talicia is designed to address the increasing resistance of H. pylori bacteria to the antibiotics commonly used in current standard-of-care therapies and the imperative need for new treatments.5 Talicia’s approval is based, in part, on the results of two positive Phase 3 studies in the U.S. for the treatment of H. pylori-positive adult patients complaining of epigastric pain and/or discomfort.

The confirmatory Phase 3 study of Talicia demonstrated 84% eradication of H. pylori infection with Talicia vs. 58% in the active comparator arm (p<0.0001). Further, in an analysis of data from this study, it was observed that subjects with measurable blood levels of drug at Day 13 had response rates of 90.3% in the Talicia arm vs. 64.7% in the active comparator arm3. No resistance to rifabutin, a key component of Talicia, was detected in the study.  Treatment discontinuation due to an adverse reaction occurred in 1% of patients (4/305) receiving Talicia. The adverse reactions leading to the patients’ discontinuation of Talicia were nausea and vomiting, nausea, nasal congestion, and nasopharyngitis, respectively.

Indication and usage

Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial, indicated for the treatment of Helicobacter pylori infection in adults.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

Important safety information contraindications

Known hypersensitivity to omeprazole, amoxicillin or any other beta-lactam antibacterial drugs, rifabutin or any other rifamycin, or any component of Talicia.

Rilpivirine-containing products.

Delavirdine.

Voriconazole.

Warnings and precautions

Hypersensitivity Reactions: Serious and occasionally fatal reactions (e.g., anaphylaxis) have been reported with components of Talicia. If hypersensitivity reactions occur, discontinue Talicia and institute immediate therapy (e.g., anaphylaxis management).

Clostridioides difficile-Associated Diarrhea (CDAD): Evaluate if diarrhea occurs.

Reduction in the Efficacy of Hormonal Contraceptives: Additional non-hormonal highly effective methods of contraception should be used while taking Talicia.

Acute Interstitial Nephritis (AIN): Observed in patients taking Proton Pump Inhibitors (PPIs) and penicillins. Discontinue Talicia if AIN develops.

Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or exacerbation of existing disease; discontinue TALICIA and evaluate.

Adverse reactions

Most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis.

Drug interactions

Components of Talicia have the potential for clinically important drug interactions.

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

We know health is wealth and that is very much related with hygiene. Health and hygiene go hands in hands. The word hygiene is derived from Hygeiea, the…
Hygiene

Hygiene

A high standard of personal hygiene is essential for people preparing food. Hands should always be washed with soap or ash before handling food, particularly…
Hygiene-related diseases

Hygiene-related diseases

Athlete’s Foot (tinea pedis) Athlete’s foot, or tinea pedis, is an infection of the skin and feet that can be caused by a variety of different…
WHO on hygiene education

WHO on hygiene education

Scope of hygiene education Community-based surveillance Effective and sustainable programmes for the surveillance of water supplies re- quire the active…
What’s a healthy weight for you?

What’s a healthy weight for you?

According to the National Center for Health Statistics, about 43 percent of women and 38 percent of men 60 and older are obese. However, some evidence…
Schizophrenia and your brain

Schizophrenia and your brain

People who have schizophrenia may hear voices or see things that aren’t real. But what happens inside the brain of someone who has schizophrenia?…
Brief visit to severely polluted city can up biomarkers of heart disease

Brief visit to severely polluted city can up biomarkers of heart disease

SAUMYA JOSEPH Reuters Health - Air pollution has often been linked with increased heart disease risk, but a "natural experiment" involving travelers…
World Hospice and Palliative Care Day observes in Dhaka

World Hospice and Palliative Care Day observes in Dhaka

World Hospice and Palliative Care Day’ is being celebrated around the world with the motto ‘My Care, My Rights’. In line with that,…
Middle-income countries are hardest hit by cardiovascular disease in Europe

Middle-income countries are hardest hit by cardiovascular disease in Europe

Middle-income countries shoulder the bulk of morbidity and mortality from cardiovascular disease (CVD) in Europe, according to a major report published…
Use of pain, sleep drugs ups risk of frailty in the elderly

Use of pain, sleep drugs ups risk of frailty in the elderly

Prescription pain and sleep drug use is significantly associated with increased incidence of frailty, according to a study published in the December issue…
Two drugs make inroads against aggressive breast cancers

Two drugs make inroads against aggressive breast cancers

Two experimental drugs show real promise against an aggressive, treatment-resistant form of breast cancer that's spread to other parts of the body,…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting